TrialLancet (London, England)2024

Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study.

Ahmet Ozen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.